Your product also is going to cost $30,000 vs. $7,500 and is not going to be approved in the U.S. until at least 2013...according to the CEO's interview on CNN on Youtube. In this economy, getting physicians to fork over that much money has proven very difficult. It killed Dendreon...as the out-of-pocket cost for Provenge was prohibitive and physician cash flows are not enough to front huge purchases. MELA is first to market in U.S., two years ahead and with a very low out of pocket cost.
I agree. Even with medicare approval for DNDN, the $90,000 upfront cost to the doctor is a lot. Of course, they may overcome that with a financing deal until full reimbusement. This is an important drug.